BGB-21447

DRUG2 trials

Sponsors

BeOne Medicines

Conditions

HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast CancerRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-cell LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin Lymphoma

Phase 1

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

TerminatedNCT05828589

BeOne MedicinesRefractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-cell Lymphoma, Refractory Follicular Lymphoma +11

Start: 2023-06-20End: 2026-06-08Updated: 2026-07-14

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

RecruitingNCT06756932

BeOne MedicinesHER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer

Start: 2025-02-04End: 2027-07-30Target: 120Updated: 2026-09-14

Related Papers

Abstract 4663: BGB-21447, a next-generation Bcl-2 inhibitor, demonstrates superior potency and overcomes Venetoclax resistance in preclinical models of hematologic malignancies

Cancer Research2026-04-03

Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients with previously treated HR+/HER2− metastatic breast cancer

Clinical Cancer Research2026-02-17

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Blood2025-11-03